Immunohistochemistry Market by Product Category (Antibodies, Detection Systems, Chromogens & Counterstains), Technology (Chromogenic IHC, Immunofluorescence, Signal Amplification), Specimen Type, Application, Indication, End User - Global Forecast 2025-20
Description
The Immunohistochemistry Market was valued at USD 3.15 billion in 2024 and is projected to grow to USD 3.33 billion in 2025, with a CAGR of 6.10%, reaching USD 5.07 billion by 2032.
A concise orientation to immunohistochemistry advancements, clinical drivers, and strategic imperatives shaping diagnostic and research applications worldwide
Immunohistochemistry continues to sit at the intersection of diagnostic refinement and translational research, driven by advances in reagent specificity, automation, and digital interpretation. The technology’s ability to localize biomarkers within tissue architecture has expanded its role beyond classical pathology into companion diagnostics, biomarker discovery, and therapeutic stratification. As institutions seek to increase throughput, reproducibility, and clinical relevance, laboratories are investing in integrated solutions that combine robust chemistry, reliable instrumentation, and analytics-driven decision support.
Consequently, stakeholders across the value chain-from reagent manufacturers to laboratory directors-are confronting new operational imperatives. These include the need to standardize pre‑analytic workflows, validate novel detection chemistries across platforms, and bridge laboratory information systems with imaging outputs. The result is a heightened emphasis on cross-disciplinary collaboration between clinical pathologists, molecular scientists, and informatics teams, which is reshaping procurement criteria and vendor relationships. Looking ahead, sustained clinical adoption will depend on demonstrable gains in diagnostic confidence, streamlined regulatory pathways, and cost‑effective integration into laboratory workflows.
How technological convergence, digital pathology adoption, and reagent innovations are rapidly reshaping workflow efficiency and diagnostic accuracy across laboratories
The landscape of immunohistochemistry is undergoing transformative shifts as digital pathology, multiplex assays, and automation converge to create new diagnostic paradigms. Increased confidence in whole slide imaging and image analysis algorithms is enabling pathologists to incorporate quantitation into routine interpretations, thereby reducing subjectivity and accelerating turnaround times. Simultaneously, reagent innovation-particularly in recombinant antibody development and polymer‑based detection systems-has improved specificity and reduced background, enabling clearer signal resolution for low‑abundance targets.
These developments are complemented by instrument evolution; automated stainers and integrated imaging systems reduce hands‑on time and support standardized workflows across institutions of varying scale. In parallel, the emergence of cloud‑enabled data platforms and regulatory clarity around digital diagnostics are creating a pathway for broader clinical adoption. As a result, the market is moving from discrete product purchases toward bundled solutions that promise validated end‑to‑end performance. This shift places a premium on cross‑vendor compatibility and comprehensive validation services, with implications for procurement strategy and long‑term capital planning.
Assessing the downstream operational, supply chain, and pricing consequences of the United States tariff changes instituted in 2025 on immunohistochemistry inputs
The tariff adjustments implemented in the United States during 2025 introduced a set of operational and strategic pressures across the immunohistochemistry supply chain. Increased duties on certain imported reagents and components raised the landed cost of critical inputs, prompting purchasing teams to reassess sourcing strategies and inventory policies. In response, many laboratory purchasing departments extended reorder lead times, increased safety stock, and accelerated qualification of domestically produced alternatives where possible. Those measures, while stabilizing supply, also introduced working capital and storage considerations that affected budgetary allocations.
Beyond procurement, the tariff landscape catalyzed supplier negotiations and contractual re‑pricing, with some vendors absorbing portions of cost increases to protect long‑term contracts and others passing through incremental expenses. This divergence influenced partner selection criteria, as laboratories weighed total cost of ownership against performance consistency and supply reliability. Importantly, research laboratories and clinical sites with tight reimbursement margins experienced the most acute pressure, stimulating interest in assay consolidation and multiplexing approaches to reduce per‑test reagent consumption. Finally, the tariff environment accelerated regional supplier development and strategic nearshoring initiatives, which may enhance resilience but require investment in local manufacturing scale and quality systems over time.
Segment-level intelligence revealing reagent, instrument, and software and services dynamics that define product development, procurement, and deployment priorities
A granular view across product groupings highlights nuanced dynamics that should inform commercial and operational planning. Within reagents and kits, antibodies remain central, with a trend toward recombinant formats that offer lot‑to‑lot consistency and engineered specificity; monoclonal, polyclonal, and recombinant antibody formats each present distinct validation and cost implications for end users. Buffers and mounting media remain foundational to reliable staining outcomes, with antigen retrieval buffers, mounting media, and washing buffers influencing pre‑analytic variability and downstream image quality. Detection reagents have diversified into enzyme‑labeled systems, fluorophore‑labeled solutions, and polymer‑based detection technologies, each suited to different laboratory throughput and multiplexing requirements. Substrates and chromogens such as AEC and DAB retain importance for brightfield workflows but are increasingly complemented by chromogenic alternatives in multiplex assays.
Turning to instruments, automated stainers have bifurcated into closed and open system architectures that influence workflow flexibility and reagent lock‑in considerations. Imaging systems now bundle digital pathology software with whole slide imaging capabilities, altering how pathology groups think about data lifecycle and case review. Microscopy platforms-spanning bright field, confocal, and fluorescence microscopes-continue to support specialized applications from routine diagnostics to high‑content research. Finally, software and services have assumed a strategic role, with consulting, data analysis software, maintenance, and training services determining the success of deployments and the speed at which new techniques move into routine use. Together, these segment‑level dynamics reveal where investment will translate into operational gains and where validation burdens may impede adoption.
Regional competitive and adoption contours across the Americas, Europe Middle East and Africa, and Asia-Pacific highlighting infrastructure, regulation, and talent factors
Regional dynamics continue to reshape adoption, investment, and innovation trajectories across continents with clear differentiation in infrastructure, regulatory frameworks, and workforce capacity. In the Americas, advanced pathology networks and centralized reference laboratories drive demand for automation and digital pathology integration, while decentralised clinical laboratories seek scalable, validated solutions to support diagnostic expansion. Regulatory pathways and reimbursement structures influence uptake, with private‑public collaboration accelerating translational studies and clinical validation programs.
Across Europe, the Middle East and Africa, adoption patterns vary significantly between mature healthcare systems with robust laboratory accreditation and emerging markets focused on capacity building. In parts of Europe, harmonized regulatory standards and established procurement frameworks support multi‑site deployments and cross‑border validation studies, whereas in the Middle East and Africa, investment often centres on upgrading core infrastructure and training to expand routine histopathology capabilities. In Asia‑Pacific, a combination of high population density, expanding clinical trials activity, and government initiatives to modernize laboratory services is driving rapid demand for integrated solutions. Regional supply chain strategies and local manufacturing initiatives further influence partner selection and long‑term procurement planning in each geography.
Corporate behavior and strategic positioning insights examining innovation pathways, partnership models, and portfolio evolution among leading immunohistochemistry suppliers
Corporate behavior in the immunohistochemistry ecosystem reflects a dual focus on technology differentiation and commercial scale. Leading suppliers are investing in modular platforms that allow customers to mix and match reagents with instrument capabilities, thereby reducing barriers to adoption and protecting installed bases through compatibility. Simultaneously, there is an observable shift toward value‑added services-such as assay validation packages, regulatory support, and training programs-that extend vendor relationships beyond the point of sale. These services improve customer stickiness and reduce the burden on laboratory teams responsible for implementing complex assays.
New entrants and specialized reagent developers are advancing niche innovations, particularly in recombinant antibody platforms and multiplex detection chemistries, which challenges incumbents to accelerate internal R&D or pursue targeted partnerships and acquisitions. Partnership models that combine distribution strength with technical expertise are proving effective at entering regulated markets, while collaborative validation studies with academic centres provide clinical credibility. Across the board, companies are prioritizing scalable manufacturing processes, supply chain transparency, and regulatory readiness as core elements of competitiveness in both clinical and research segments.
Actionable strategic imperatives for manufacturers, laboratories, and payers to accelerate adoption, optimize supply resilience, and sustain regulatory compliance
Industry leaders should pursue a set of pragmatic initiatives to capture near‑term opportunities while building resilience for future disruption. First, invest in standardized validation kits and cross‑platform compatibility testing to reduce the onboarding burden for clinical laboratories and accelerate adoption of new reagents and detection systems. This will shorten time to clinical utility and lower total cost of ownership for customers. Second, diversify supply chain sources and develop regional manufacturing or distribution partnerships to mitigate tariff exposure and shorten lead times; nearshoring and multi‑source strategies will strengthen continuity of supply.
Third, expand service offerings around training, assay validation, and post‑market support to deepen customer engagement and create recurring revenue streams. Fourth, prioritize data integration capabilities by ensuring digital pathology systems and analysis software conform to interoperability standards; this will enable seamless workflow integration and facilitate adoption by enterprise customers. Fifth, align product roadmaps with regulatory expectations by investing early in clinical validation and regulatory strategy, which will reduce barriers to market access. Collectively, these actions will enhance commercial differentiation, improve operational resilience, and support sustainable growth across diverse laboratory environments.
Robust mixed-method research design detailing primary and secondary techniques, validation workflows, and quality controls underpinning the analysis
The study employed a mixed‑method research design to ensure depth, accuracy, and practical relevance. Primary qualitative data were gathered through structured interviews with pathologists, laboratory directors, procurement professionals, and product managers to capture lived operational challenges and vendor performance perceptions. These insights were triangulated with quantitative evidence derived from device registries, regulatory filings, and peer‑reviewed literature to validate recurring themes and identify technology adoption patterns. In addition, laboratory workflow observations and assay validation case studies were analyzed to assess real‑world performance and reproducibility across platforms.
To ensure rigor, data collection adhered to preset protocols for respondent selection, question framing, and anonymized reporting. Cross‑validation techniques were applied by comparing independent data streams and conducting sensitivity checks on thematic interpretations. Subject‑matter experts reviewed draft findings to confirm technical accuracy and practical applicability. Finally, quality controls included traceable documentation of data provenance, versioned analysis scripts for reproducibility, and an audit trail for editorial decisions, ensuring that conclusions reflect robust evidence and are defensible for strategic decision making.
Synthesis of diagnostic, research, and commercial trajectories in immunohistochemistry with emphasis on translational impact and operational readiness
Bringing together diagnostic needs, technology advances, and commercial realities produces a coherent narrative about the maturation of immunohistochemistry. The field is transitioning from discrete, reagent‑centric purchases to integrated solutions that encompass validated chemistries, automated staining, digital imaging, and analytic software. This evolution enhances diagnostic precision and supports new clinical applications, but it also elevates the importance of interoperability, standardized validation, and sustained post‑market support. As laboratories modernize, they will seek partners that can demonstrate end‑to‑end reliability and deliver services that reduce implementation risk.
Operational readiness and translational impact will be determined by the ability of stakeholders to align technical performance with clinical workflows, regulatory expectations, and budgetary realities. Companies that invest in cross‑platform validation, supply chain resilience, and service models that lower the burden on laboratory teams will secure competitive advantage. Ultimately, the most successful actors will be those who can translate technical innovation into measurable improvements in diagnostic workflows and patient care while maintaining the flexibility to adapt to regional and policy shifts.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to immunohistochemistry advancements, clinical drivers, and strategic imperatives shaping diagnostic and research applications worldwide
Immunohistochemistry continues to sit at the intersection of diagnostic refinement and translational research, driven by advances in reagent specificity, automation, and digital interpretation. The technology’s ability to localize biomarkers within tissue architecture has expanded its role beyond classical pathology into companion diagnostics, biomarker discovery, and therapeutic stratification. As institutions seek to increase throughput, reproducibility, and clinical relevance, laboratories are investing in integrated solutions that combine robust chemistry, reliable instrumentation, and analytics-driven decision support.
Consequently, stakeholders across the value chain-from reagent manufacturers to laboratory directors-are confronting new operational imperatives. These include the need to standardize pre‑analytic workflows, validate novel detection chemistries across platforms, and bridge laboratory information systems with imaging outputs. The result is a heightened emphasis on cross-disciplinary collaboration between clinical pathologists, molecular scientists, and informatics teams, which is reshaping procurement criteria and vendor relationships. Looking ahead, sustained clinical adoption will depend on demonstrable gains in diagnostic confidence, streamlined regulatory pathways, and cost‑effective integration into laboratory workflows.
How technological convergence, digital pathology adoption, and reagent innovations are rapidly reshaping workflow efficiency and diagnostic accuracy across laboratories
The landscape of immunohistochemistry is undergoing transformative shifts as digital pathology, multiplex assays, and automation converge to create new diagnostic paradigms. Increased confidence in whole slide imaging and image analysis algorithms is enabling pathologists to incorporate quantitation into routine interpretations, thereby reducing subjectivity and accelerating turnaround times. Simultaneously, reagent innovation-particularly in recombinant antibody development and polymer‑based detection systems-has improved specificity and reduced background, enabling clearer signal resolution for low‑abundance targets.
These developments are complemented by instrument evolution; automated stainers and integrated imaging systems reduce hands‑on time and support standardized workflows across institutions of varying scale. In parallel, the emergence of cloud‑enabled data platforms and regulatory clarity around digital diagnostics are creating a pathway for broader clinical adoption. As a result, the market is moving from discrete product purchases toward bundled solutions that promise validated end‑to‑end performance. This shift places a premium on cross‑vendor compatibility and comprehensive validation services, with implications for procurement strategy and long‑term capital planning.
Assessing the downstream operational, supply chain, and pricing consequences of the United States tariff changes instituted in 2025 on immunohistochemistry inputs
The tariff adjustments implemented in the United States during 2025 introduced a set of operational and strategic pressures across the immunohistochemistry supply chain. Increased duties on certain imported reagents and components raised the landed cost of critical inputs, prompting purchasing teams to reassess sourcing strategies and inventory policies. In response, many laboratory purchasing departments extended reorder lead times, increased safety stock, and accelerated qualification of domestically produced alternatives where possible. Those measures, while stabilizing supply, also introduced working capital and storage considerations that affected budgetary allocations.
Beyond procurement, the tariff landscape catalyzed supplier negotiations and contractual re‑pricing, with some vendors absorbing portions of cost increases to protect long‑term contracts and others passing through incremental expenses. This divergence influenced partner selection criteria, as laboratories weighed total cost of ownership against performance consistency and supply reliability. Importantly, research laboratories and clinical sites with tight reimbursement margins experienced the most acute pressure, stimulating interest in assay consolidation and multiplexing approaches to reduce per‑test reagent consumption. Finally, the tariff environment accelerated regional supplier development and strategic nearshoring initiatives, which may enhance resilience but require investment in local manufacturing scale and quality systems over time.
Segment-level intelligence revealing reagent, instrument, and software and services dynamics that define product development, procurement, and deployment priorities
A granular view across product groupings highlights nuanced dynamics that should inform commercial and operational planning. Within reagents and kits, antibodies remain central, with a trend toward recombinant formats that offer lot‑to‑lot consistency and engineered specificity; monoclonal, polyclonal, and recombinant antibody formats each present distinct validation and cost implications for end users. Buffers and mounting media remain foundational to reliable staining outcomes, with antigen retrieval buffers, mounting media, and washing buffers influencing pre‑analytic variability and downstream image quality. Detection reagents have diversified into enzyme‑labeled systems, fluorophore‑labeled solutions, and polymer‑based detection technologies, each suited to different laboratory throughput and multiplexing requirements. Substrates and chromogens such as AEC and DAB retain importance for brightfield workflows but are increasingly complemented by chromogenic alternatives in multiplex assays.
Turning to instruments, automated stainers have bifurcated into closed and open system architectures that influence workflow flexibility and reagent lock‑in considerations. Imaging systems now bundle digital pathology software with whole slide imaging capabilities, altering how pathology groups think about data lifecycle and case review. Microscopy platforms-spanning bright field, confocal, and fluorescence microscopes-continue to support specialized applications from routine diagnostics to high‑content research. Finally, software and services have assumed a strategic role, with consulting, data analysis software, maintenance, and training services determining the success of deployments and the speed at which new techniques move into routine use. Together, these segment‑level dynamics reveal where investment will translate into operational gains and where validation burdens may impede adoption.
Regional competitive and adoption contours across the Americas, Europe Middle East and Africa, and Asia-Pacific highlighting infrastructure, regulation, and talent factors
Regional dynamics continue to reshape adoption, investment, and innovation trajectories across continents with clear differentiation in infrastructure, regulatory frameworks, and workforce capacity. In the Americas, advanced pathology networks and centralized reference laboratories drive demand for automation and digital pathology integration, while decentralised clinical laboratories seek scalable, validated solutions to support diagnostic expansion. Regulatory pathways and reimbursement structures influence uptake, with private‑public collaboration accelerating translational studies and clinical validation programs.
Across Europe, the Middle East and Africa, adoption patterns vary significantly between mature healthcare systems with robust laboratory accreditation and emerging markets focused on capacity building. In parts of Europe, harmonized regulatory standards and established procurement frameworks support multi‑site deployments and cross‑border validation studies, whereas in the Middle East and Africa, investment often centres on upgrading core infrastructure and training to expand routine histopathology capabilities. In Asia‑Pacific, a combination of high population density, expanding clinical trials activity, and government initiatives to modernize laboratory services is driving rapid demand for integrated solutions. Regional supply chain strategies and local manufacturing initiatives further influence partner selection and long‑term procurement planning in each geography.
Corporate behavior and strategic positioning insights examining innovation pathways, partnership models, and portfolio evolution among leading immunohistochemistry suppliers
Corporate behavior in the immunohistochemistry ecosystem reflects a dual focus on technology differentiation and commercial scale. Leading suppliers are investing in modular platforms that allow customers to mix and match reagents with instrument capabilities, thereby reducing barriers to adoption and protecting installed bases through compatibility. Simultaneously, there is an observable shift toward value‑added services-such as assay validation packages, regulatory support, and training programs-that extend vendor relationships beyond the point of sale. These services improve customer stickiness and reduce the burden on laboratory teams responsible for implementing complex assays.
New entrants and specialized reagent developers are advancing niche innovations, particularly in recombinant antibody platforms and multiplex detection chemistries, which challenges incumbents to accelerate internal R&D or pursue targeted partnerships and acquisitions. Partnership models that combine distribution strength with technical expertise are proving effective at entering regulated markets, while collaborative validation studies with academic centres provide clinical credibility. Across the board, companies are prioritizing scalable manufacturing processes, supply chain transparency, and regulatory readiness as core elements of competitiveness in both clinical and research segments.
Actionable strategic imperatives for manufacturers, laboratories, and payers to accelerate adoption, optimize supply resilience, and sustain regulatory compliance
Industry leaders should pursue a set of pragmatic initiatives to capture near‑term opportunities while building resilience for future disruption. First, invest in standardized validation kits and cross‑platform compatibility testing to reduce the onboarding burden for clinical laboratories and accelerate adoption of new reagents and detection systems. This will shorten time to clinical utility and lower total cost of ownership for customers. Second, diversify supply chain sources and develop regional manufacturing or distribution partnerships to mitigate tariff exposure and shorten lead times; nearshoring and multi‑source strategies will strengthen continuity of supply.
Third, expand service offerings around training, assay validation, and post‑market support to deepen customer engagement and create recurring revenue streams. Fourth, prioritize data integration capabilities by ensuring digital pathology systems and analysis software conform to interoperability standards; this will enable seamless workflow integration and facilitate adoption by enterprise customers. Fifth, align product roadmaps with regulatory expectations by investing early in clinical validation and regulatory strategy, which will reduce barriers to market access. Collectively, these actions will enhance commercial differentiation, improve operational resilience, and support sustainable growth across diverse laboratory environments.
Robust mixed-method research design detailing primary and secondary techniques, validation workflows, and quality controls underpinning the analysis
The study employed a mixed‑method research design to ensure depth, accuracy, and practical relevance. Primary qualitative data were gathered through structured interviews with pathologists, laboratory directors, procurement professionals, and product managers to capture lived operational challenges and vendor performance perceptions. These insights were triangulated with quantitative evidence derived from device registries, regulatory filings, and peer‑reviewed literature to validate recurring themes and identify technology adoption patterns. In addition, laboratory workflow observations and assay validation case studies were analyzed to assess real‑world performance and reproducibility across platforms.
To ensure rigor, data collection adhered to preset protocols for respondent selection, question framing, and anonymized reporting. Cross‑validation techniques were applied by comparing independent data streams and conducting sensitivity checks on thematic interpretations. Subject‑matter experts reviewed draft findings to confirm technical accuracy and practical applicability. Finally, quality controls included traceable documentation of data provenance, versioned analysis scripts for reproducibility, and an audit trail for editorial decisions, ensuring that conclusions reflect robust evidence and are defensible for strategic decision making.
Synthesis of diagnostic, research, and commercial trajectories in immunohistochemistry with emphasis on translational impact and operational readiness
Bringing together diagnostic needs, technology advances, and commercial realities produces a coherent narrative about the maturation of immunohistochemistry. The field is transitioning from discrete, reagent‑centric purchases to integrated solutions that encompass validated chemistries, automated staining, digital imaging, and analytic software. This evolution enhances diagnostic precision and supports new clinical applications, but it also elevates the importance of interoperability, standardized validation, and sustained post‑market support. As laboratories modernize, they will seek partners that can demonstrate end‑to‑end reliability and deliver services that reduce implementation risk.
Operational readiness and translational impact will be determined by the ability of stakeholders to align technical performance with clinical workflows, regulatory expectations, and budgetary realities. Companies that invest in cross‑platform validation, supply chain resilience, and service models that lower the burden on laboratory teams will secure competitive advantage. Ultimately, the most successful actors will be those who can translate technical innovation into measurable improvements in diagnostic workflows and patient care while maintaining the flexibility to adapt to regional and policy shifts.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven image analysis platforms to enhance diagnostic accuracy and throughput in immunohistochemistry workflows
- 5.2. Development and adoption of multiplex fluorescent IHC assays for simultaneous detection of multiple biomarkers in oncology research
- 5.3. Expansion of automated IHC staining systems with digital pathology connectivity for streamlined clinical laboratory operations
- 5.4. Rising demand for novel isotype-specific primary antibodies improving specificity in complex tissue immunohistochemistry studies
- 5.5. Implementation of immunohistochemistry-based companion diagnostic assays for personalized cancer immunotherapy selection
- 5.6. Increasing use of nanotechnology-enabled detection reagents to amplify signal sensitivity in low-abundance antigen identification
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Immunohistochemistry Market, by Product Category
- 8.1. Antibodies
- 8.1.1. Primary Antibodies
- 8.1.1.1. Monoclonal
- 8.1.1.1.1. Mouse
- 8.1.1.1.2. Rabbit
- 8.1.1.2. Polyclonal
- 8.1.1.3. Recombinant Monoclonal
- 8.1.1.4. Recombinant Fragments
- 8.1.1.4.1. scFv
- 8.1.1.4.2. Fab
- 8.1.2. Secondary Antibodies
- 8.1.2.1. Enzyme-Conjugated
- 8.1.2.2. Biotinylated
- 8.1.2.3. Fluorophore-Conjugated
- 8.1.2.4. Unconjugated
- 8.2. Detection Systems
- 8.2.1. Polymer
- 8.2.2. Avidin-Biotin
- 8.2.3. Tyramide Amplification
- 8.3. Chromogens & Counterstains
- 8.3.1. DAB
- 8.3.2. AEC
- 8.3.3. Fast Red
- 8.3.4. Hematoxylin
- 8.4. Ancillary Reagents
- 8.4.1. Retrieval Buffers
- 8.4.2. Blocking Reagents
- 8.4.3. Wash Buffers
- 8.5. Kits & Panels
- 8.5.1. Single-Marker Kits
- 8.5.2. Multiplex Panels
- 9. Immunohistochemistry Market, by Technology
- 9.1. Chromogenic IHC
- 9.1.1. HRP/DAB
- 9.1.2. AP/Red
- 9.1.3. Dual Enzyme
- 9.2. Immunofluorescence
- 9.2.1. Singleplex IF
- 9.2.2. Multiplex IF
- 9.2.2.1. 2–3 Plex
- 9.2.2.2. 4–7 Plex
- 9.2.2.3. 8+ Plex
- 9.3. Signal Amplification
- 9.3.1. Tyramide Signal Amplification
- 9.3.2. Biotin-Based Amplification
- 9.4. Metal-Conjugated IHC
- 9.4.1. Mass Cytometry-Compatible
- 9.4.2. MIBI-Compatible
- 10. Immunohistochemistry Market, by Specimen Type
- 10.1. FFPE Tissue
- 10.1.1. Resection
- 10.1.2. Biopsy
- 10.2. Frozen Tissue
- 10.2.1. Cryosections
- 10.3. Cytology Specimens
- 10.3.1. Smears
- 10.3.2. Liquid-Based Preparations
- 10.4. Tissue Microarrays
- 11. Immunohistochemistry Market, by Application
- 11.1. Clinical Diagnostics
- 11.1.1. Oncology
- 11.1.1.1. Solid Tumors
- 11.1.1.2. Hematopathology
- 11.1.2. Infectious Disease
- 11.1.3. Transplant Immunopathology
- 11.1.4. Neuropathology
- 11.1.5. Cardiovascular Pathology
- 11.1.6. Companion Diagnostics
- 11.2. Research & Drug Discovery
- 11.2.1. Basic Research
- 11.2.2. Translational Research
- 11.2.3. Target Validation
- 11.2.4. Biomarker Discovery
- 11.2.5. Toxicologic Pathology
- 11.3. Veterinary Pathology
- 11.4. Forensic Pathology
- 11.5. Education & Training
- 12. Immunohistochemistry Market, by Indication
- 12.1. Oncology
- 12.1.1. Breast Cancer
- 12.1.2. Lung Cancer
- 12.1.3. Colorectal Cancer
- 12.1.4. Prostate Cancer
- 12.1.5. Melanoma
- 12.1.6. Lymphoma
- 12.1.7. Brain Tumors
- 12.2. Infectious Diseases
- 12.2.1. Viral
- 12.2.2. Bacterial
- 12.2.3. Fungal
- 12.3. Autoimmune & Inflammatory
- 12.3.1. Systemic Autoimmune
- 12.3.2. Gastrointestinal Inflammatory
- 12.4. Neurological Disorders
- 12.4.1. Neurodegenerative
- 12.5. Renal & Hepatic
- 12.5.1. Renal Disease
- 12.5.2. Hepatic Disease
- 13. Immunohistochemistry Market, by End User
- 13.1. Hospital Laboratories
- 13.1.1. Community Hospitals
- 13.1.2. Academic Medical Centers
- 13.2. Reference Laboratories
- 13.3. Academic & Research Institutes
- 13.4. Pharmaceutical & Biotechnology
- 13.4.1. In-House Labs
- 13.4.2. Outsourced Partners
- 13.5. Contract Research Organizations
- 13.6. Veterinary Pathology Laboratories
- 14. Immunohistochemistry Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Immunohistochemistry Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Immunohistochemistry Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. F. Hoffmann-La Roche Ltd
- 17.3.2. Danaher Corporation
- 17.3.3. Thermo Fisher Scientific Inc.
- 17.3.4. Agilent Technologies, Inc.
- 17.3.5. Merck KGaA
- 17.3.6. Abbott Laboratories
- 17.3.7. Bio-Rad Laboratories, Inc.
- 17.3.8. PerkinElmer, Inc.
- 17.3.9. Cell Signaling Technology, Inc.
- 17.3.10. Abcam plc
- 17.3.11. Becton, Dickinson and Company
- 17.3.12. Biogenex Laboratories, Inc.
- 17.3.13. Enzo Life Sciences, Inc.
- 17.3.14. Histo-Line Laboratories
- 17.3.15. Leica Biosystems Nussloch GmbH
- 17.3.16. Miltenyi Biotec B.V. & Co. KG
- 17.3.17. Novus Biologicals, LLC
- 17.3.18. OriGene Technologies, Inc.
- 17.3.19. R&D Systems, Inc.
- 17.3.20. Santa Cruz Biotechnology, Inc.
- 17.3.21. Sigma-Aldrich Co. LLC
- 17.3.22. Takara Bio Inc.
- 17.3.23. Vector Laboratories, Inc.
- 17.3.24. Wako Pure Chemical Industries, Ltd.
- 17.3.25. ZenBio, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
